One ACED project is focused on developing biomarkers for the early detection of ovarian cancer, with the goal of commercializing any resulting tests.

The company has received certification under Europe's In Vitro Diagnostic Regulation for a number of tests recently.

The paper-based card separates plasma from whole-blood samples, allowing them to be used for HIV viral load testing.

NEW YORK – After acquiring Lucira Health in a bankruptcy auction in 2023, Pfizer has decided to shut down the business, a Pfizer spokesperson told GenomeWeb.

The company will use the lab to run its PromarkerD proteomic blood test for identifying individuals at risk of diabetes-related chronic kidney disease.

The firm's Qlucore Diagnostics 1.0 for BCP-ALL software is used to aid the diagnosis and treatment of B-cell precursor acute lymphoblastic leukemia.

The group recently published a case-control study showing high sensitivity and specificity, with little drop in early-stage disease, compared to late-stage cancer.

While electronic exchange of orders and results is commonplace in the commercial lab world, public health labs struggle with inconsistent levels of connectivity.

The firm will use the funding to bring the test to market in the UK, and it plans to soon start a Series A funding round to support expansion into the US market.

The researchers will conduct a five-year study to evaluate the firm's collection device and test in patients without symptoms of chronic gastroesophageal reflux disease.

The Santa Clara, California-based firm said that its diagnostics and life sciences revenues rose 4 percent year over year.

The Irvine, California-based firm's CitoCBC test cartridges and automated hematology analyzer are used to determine 16 parameters from a whole blood sample.